Arcturus signs $200M upfront collaboration with CSL Seqirus for self-amplifying mRNA vaccines

Arcturus Therapeutics Holdings Inc.

Arcturus receives $200M upfront; eligible for >$1.3B development and >$3B commercial milestones.
40% net profit share on COVID-19 vaccines; up to double-digit royalties on flu, pandemic, and 3 other respiratory vaccines.
Collaboration covers self-amplifying mRNA vaccines for COVID-19, influenza, pandemic preparedness, and three other respiratory diseases.
CSL Seqirus leads development and commercialization; Arcturus provides STARR technology and LUNAR delivery platform.
Transaction subject to HSR Act waiting period; J.P. Morgan advised Arcturus.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Arcturus Therapeutics Holdings Inc. entered into Collaboration and License Agreement with CSL Seqirus, Inc. valued at Up-front payment of $200 million; development milestones totaling more than $1.3 billion; commercial (effective 2022-11-01).

Action: entry
Agreement: collaboration
Counterparty: CSL Seqirus, Inc.
Value: Up-front payment of $200 million; development milestones totaling more than $1.3 billion; commercial
Effective: 2022-11-01

Exact text from the filing

On November 1, 2022, Arcturus Therapeutics Holdings Inc. ("Arcturus") entered into a Collaboration and License Agreement (the "Collaboration Agreement") with CSL Seqirus, Inc., a part of CSL Limited ("CSL Seqirus"), one of the world’s leading influenza vaccine providers, for the research, development, manufacture and global commercialization of self-amplifying mRNA vaccines.

View on SEC.gov

Browse all material agreements →

Arcturus Therapeutics Holdings Inc. filing history →

Source: SEC EDGAR

accession 0001193805-22-001470

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.